Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.
If you take CBD oil, you can take steps to try to prevent failing a drug test:
There are many distinctions between marijuana and hemp that relate to CBD oil. Marijuana contains both THC (the "high"-inducing element) and CBD. Hemp contains CBD and only trace amounts of THC.
Drug tests look for tetrahydrocannabinol (THC), which is the element in marijuana that causes a high. CBD oils can have trace amounts of THC even if they're labeled “THC-free.” The FDA does not regulate these products, and mislabeling is common.
These compounds were derived from a full-spectrum product rather than a CBD isolate product alone. This is one reason that full-spectrum products (those containing THC) are popular.
However, the distinction between full-spectrum oils and isolates makes all the difference if you are being tested for drug use.
What are the odds that CBD oil users will test positive when subjected to illicit drug screenings? And what can be done to prevent it?
In fact, one study discovered that almost 70% of the CBD products sold online were mislabeled. This caused "potential serious harm to its consumers.” The reason for this widespread mislabeling is that CBD products are not strictly regulated by the Food and Drug Administration (FDA).
Reasons for Failing a CBD Drug Test
Although most manufacturers claim their products do not contain THC, this is not always the case.
CBD (cannabidiol) oil is a popular product for everything from pain control and anxiety to promoting sleep. However, with the rise of CBD use comes a concern about failing a drug test.
Titus said potency testing can help ensure that accurate information about the product’s cannabinoid concentrations is communicated to consumers.
The CBD industry as a whole is doing a better job of reporting testing results for the potency of the cannabinoid in their products. Leafreport’s analysis found that only 4% of brands listed test results for 10% or fewer of their products. Still, only 42% of brands test at least 90% of their products for potency and share their third-party lab results with consumers. The review also found that the potency determined by independent lab testing frequently did not match the strength advertised on product labels, with 84% of potency-tested products not testing within 10% of the advertised amount of CBD.
Dr. Stuart Titus, the former CEO of Medical Marijuana, Inc. and now a spokesperson for the family of hemp CBD brands, told Leafreport that all CBD products should be tested for contamination by an independent laboratory. Test results for the company’s brand HempMeds are available online.
The Feds Are Coming For Delta-8 THC
“Potency testing is important as consumers want to know about the active ingredients – and how much they will be taking per serving,” Titus said. “Often, children with epilepsy will be “dosed” or served according to their body weight and will require a specific amount of product (likely CBD) to control seizure episodes.”
An analysis from Leafreport found that only 25% of CBD products are tested for purity.
In a report published last month, online CBD educational resource Leafreport reviewed the lab analysis data for 2,946 cannabidiol (CBD) products from 136 brands to determine how many companies test their products for purity and potency. The investigation also looked for discrepancies between the amount of CBD advertised on product packaging and the actual potency revealed by lab testing. With more and more consumers trying CBD to treat health conditions including anxiety, inflammation and pain, transparency in labeling can help them achieve the results they desire.
Blackstone To Sell The Cosmopolitan Of Las Vegas For $5.65 Billion
Leafreport found that 25% of brands did not carry out any purity testing, noting that analyzing for contaminants is more expensive than potency testing. Only 13% of CBD brands carried out purity testing for at least 90% of their products to determine the presence of pesticide residue, heavy metals or microbial contamination. More than a third of brands (35%) published test results for only 10% or less of their offerings.
A recent analysis of lab testing data has found that one out of four consumer CBD products is not tested for impurities including pesticides, heavy metals and microbial contamination. The investigation also discovered that the vast majority of CBD consumer goods are not labeled with accurate information detailing the potency of the products.